A phase 2 trial of Neurocrine’s Ingrezza in Tourette syndrome has missed its primary endpoint.

Women’s health biotech ObsEva has set the terms for an IPO that could net it in the region of $87 million.

AstraZeneca has pushed back the estimated completion date for the phase 3 trial of its PD-L1 drug, a first-line treatment for non-small cell lung cancer.

Alcobra took a body blow last year when the FDA placed a clinical hold on its lead drug metadoxine, but a failed phase 3 trial has now delivered a coup de…

The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on…

As his inauguration nears, Donald Trump has interviewed an eclectic mix of candidates for his pick as National Institutes of Health (NIH) chief.

German Merck and U.S. software firm Palantir have teamed up on big data to help the pharma to combine its research with other bioinformatics.

The belief that the FDA is to undergo a major shift in thinking was given further credence as another curveball was thrown into the mix.

Most companies developing CAR-T therapies are firmly focused on blood cancers, but Celyad is bucking the trend with a trial that will include a tougher…